{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:52:42Z","timestamp":1791287562102,"version":"4.1.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","award":["CANSERV GA N. 101058620"],"award-info":[{"award-number":["CANSERV GA N. 101058620"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cutaneous melanoma (CM) is a highly immunogenic and therapeutically intricate solid tumor, exemplifying the interactions between tumors and the immune system. Despite the significant enhancement in survival rates for patients with advanced melanoma due to immune checkpoint inhibitors (ICIs), numerous patients either exhibit resistance to these agents or develop immune evasion mechanisms. This underscores the pressing necessity to identify biological determinants of drug responses. A significant body of research indicates that epigenetic alterations, including DNA methylation, histone modifications, and ATP-dependent chromatin remodeling, are essential in modulating melanoma immunogenicity. This encompasses the modulation of antigen presentation, innate immune detection, interferon (IFN) signaling, melanoma plasticity, and the reconfiguration of the immune microenvironment. Furthermore, in contrast to genetic mutations, these mechanisms are reversible, positioning melanoma as a prime example of epigenetically regulated and potentially therapeutically targeted immune resistance. This review examines the novel insight that epigenetic therapies can enhance the immunological activity of \u201ccold\u201d or immune-excluded melanomas, transforming them into inflamed, drug-responsive tumors. This is achievable by restoring antigenicity and reactivating IFN-related pathways, leading to enhanced immune cell infiltration. The paper also addresses the necessity of longitudinal biobanking combined with integrated multi-omics analyses of epigenomics, transcriptomics, proteomics, and spatial profiling to investigate dynamic tumor\u2013immune configurations, support the validation of candidate biomarkers, and explore biologically informed patient stratification. In conclusion, we propose an integrative model connecting epigenetic vulnerability, immune reconfiguration, and biobank-driven systems biology. This model is proposed as a research framework for investigating future biomarker informed immunotherapy strategies in melanoma.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1932718","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:10:51Z","timestamp":1791285051000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Towards epigenetically informed and biobank-driven precision immunotherapy in melanoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Ludovica","family":"Ciuffreda","sequence":"first","affiliation":[{"name":"Gene expression and Cancer Model Unit, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Italia","family":"Falcone","sequence":"additional","affiliation":[{"name":"Gene expression and Cancer Model Unit, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sorino","sequence":"additional","affiliation":[{"name":"Gene expression and Cancer Model Unit, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Valenti","sequence":"additional","affiliation":[{"name":"Radiology and Diagnostic Imaging Unit, Department of Clinical and Dermatological Research, San Gallicano Dermatological Institute IRCCS","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Accetta","sequence":"additional","affiliation":[{"name":"Department of Pathology Unit, Tissue Biobank, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"De Nicola","sequence":"additional","affiliation":[{"name":"Gene expression and Cancer Model Unit, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Roglia","sequence":"additional","affiliation":[{"name":"Gynecologic Oncology Unit, Department of Experimental Clinical Oncology, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Fanciulli","sequence":"additional","affiliation":[{"name":"Gene expression and Cancer Model Unit, Department of Research, Advanced Diagnostics and Technological Innovation, Translational Research Area, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Blandino","sequence":"additional","affiliation":[{"name":"Scientific Direction, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Pescarmona","sequence":"additional","affiliation":[{"name":"Department of Pathology Unit, Tissue Biobank, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Di Martino","sequence":"additional","affiliation":[{"name":"Department of Pathology Unit, Tissue Biobank, IRCCS Regina Elena National Cancer Institute","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172920","article-title":"Melanoma skin cancer: A comprehensive review of current knowledge","volume":"17","author":"Caraviello","year":"2025","journal-title":"Cancers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"39300","DOI":"10.1038\/s41598-025-23066-z","article-title":"Global assessment of surface ultraviolet radiation and malignant skin melanoma incidence from 1990 to 2021","volume":"15","author":"Feng","year":"2025","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llaf170","article-title":"Trends in cutaneous malignant melanoma mortality in Europe from 1992 to 2021","volume":"50","author":"Send\u00edn-Mart\u00edn","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000003416","article-title":"Recent global patterns in skin cancer incidence, mortality, and prevalence","volume":"138","author":"Wang","year":"2025","journal-title":"Chin Med J (Engl)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35463","article-title":"Global burden of cutaneous melanoma incidence attributable to ultraviolet radiation in 2022","volume":"157","author":"Langselius","year":"2025","journal-title":"Int J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.11S1a161S","article-title":"Epidemiology and risk factors of melanoma: A review","volume":"11","author":"Conforti","year":"2021","journal-title":"Dermatol Pract Concept"},{"key":"B7","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1006665","article-title":"Genomic landscape of the immunogenicity regulation in skin melanomas with diverse tumor mutation burden","volume":"13","author":"Georgoulias","year":"2022","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2330","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study","volume":"35","author":"Long","year":"2024","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1403021","article-title":"Immunotherapy in melanoma: Advances, pitfalls, and future perspectives","volume":"11","author":"Sorino","year":"2024","journal-title":"Front Mol Biosci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13046-018-0820-5","article-title":"Therapeutic potential of combined BRAF\/MEK blockade in BRAF-wild type preclinical tumor models","volume":"37","author":"Del Curatolo","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1723066","article-title":"Dissecting the MAPK signaling landscape in malignant melanoma: From BRAF and NRAS mutations to precision combination therapies","volume":"13","author":"Fang","year":"2026","journal-title":"Front Cell Dev Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): Updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0109-9","article-title":"Epigenetic therapy in immune-oncology","volume":"19","author":"Jones","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13148-025-01865-5","article-title":"DNA methylation in melanoma immunotherapy: Mechanisms and therapeutic opportunities","volume":"17","author":"Deshmukh","year":"2025","journal-title":"Clin Epigenet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.010","article-title":"The hallmarks of cancer immune evasion","volume":"42","author":"Galassi","year":"2024","journal-title":"Cancer Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41571-019-0266-5","article-title":"The emerging role of epigenetic therapeutics in immuno-oncology","volume":"17","author":"Topper","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013598118","article-title":"Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma","volume":"118","author":"Falahat","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2026.1748347","article-title":"Unlocking personalized endometrial cancer treatment: The critical role of the BBIRE biobank in sample collection and distribution","volume":"13","author":"Bruno","year":"2026","journal-title":"Front Mol Biosci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12050","article-title":"NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics","volume":"11","author":"Cirenajwis","year":"2017","journal-title":"Mol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3978\/j.issn.2304-3865.2014.03.01","article-title":"Genotyping of cutaneous melanoma","volume":"3","author":"Glitza","year":"2014","journal-title":"Chin Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41392-021-00827-6","article-title":"Signal pathways of melanoma and targeted therapy","volume":"6","author":"Guo","year":"2021","journal-title":"Sig Transduct Target Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00024","article-title":"PTEN: Multiple functions in human malignant tumors","volume":"5","author":"Milella","year":"2015","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12920-015-0147-4","article-title":"DNA methylation subgroups in melanoma are associated with proliferative and immunological processes","volume":"8","author":"Lauss","year":"2015","journal-title":"BMC Med Genomics"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.226","article-title":"Methylation of PTEN as a prognostic factor in malignant melanoma of the skin","volume":"130","author":"Lahtz","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0384","article-title":"Epigenetic silencing of the PTEN gene in melanoma","volume":"66","author":"Mirmohammadsadegh","year":"2006","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.01.024","article-title":"Promoter methylation of PTEN is a significant prognostic factor in melanoma survival","volume":"136","author":"Roh","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.trecan.2016.12.003","article-title":"NLRC5\/CITA: A key player in cancer immune surveillance","volume":"3","author":"Yoshihama","year":"2017","journal-title":"Trends Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.690186","article-title":"Clinical and molecular correlates of NLRC5 expression in patients with melanoma","volume":"9","author":"Lv","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310821121","article-title":"Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I","volume":"121","author":"Sun","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2011.02.001","article-title":"The biology of cancer testis antigens: Putative function, regulation and therapeutic potential","volume":"5","author":"Fratta","year":"2011","journal-title":"Mol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.07.005","article-title":"Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy","volume":"32","author":"Sigalotti","year":"2005","journal-title":"Semin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12481","article-title":"EZH2 as a mediator of treatment resistance in melanoma","volume":"29","author":"Tiffen","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.07.007","article-title":"The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy","volume":"20","author":"Zingg","year":"2017","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1186\/s12964-024-01860-y","article-title":"cGAS\/STING in skin melanoma: From molecular mechanisms to therapeutics","volume":"22","author":"Mahin","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2021.09.028","article-title":"Dual targeting with EZH2 inhibitor and STING agonist to treat melanoma","volume":"142","author":"Emran","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jid.2021.08.437","article-title":"EZH2 inhibitor enhances the STING agonist\u2013induced antitumor immunity in melanoma","volume":"142","author":"Xu","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1038\/s41598-019-42237-3","article-title":"Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells","volume":"9","author":"Knox","year":"2019","journal-title":"Sci Rep"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0077-T","article-title":"HDAC inhibition upregulates PD-1 ligands in melanoma and augments immunotherapy with PD-1 blockade","volume":"3","author":"Woods","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091518","article-title":"Elevated HDAC4 expression is associated with reduced T-cell inflamed tumor microenvironment gene signatures and immune checkpoint inhibitor effectiveness in melanoma","volume":"17","author":"Alamoudi","year":"2025","journal-title":"Cancers"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/epigenomes6010010","article-title":"SWI\/SNF chromatin remodeling enzymes in melanoma","volume":"6","author":"Dreier","year":"2022","journal-title":"Epigenomes"},{"key":"B49","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/s12964-026-02840-0","article-title":"Enhanced IFNy response in dedifferentiated melanoma cells is due to chromatin remodeling as revealed by ATAC-seq","volume":"24","author":"S\u00e6varsson","year":"2026","journal-title":"Cell Commun Signal"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1190333","article-title":"Dysregulation in IFN-\u03b3 signaling and response: The barricade to tumor immunotherapy","volume":"14","author":"Han","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","article-title":"Toward minimal residual disease-directed therapy in melanoma","volume":"174","author":"Rambow","year":"2018","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14246118","article-title":"New insights into the phenotype switching of melanoma","volume":"14","author":"Pagliuca","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2491","article-title":"In vivo switching of human melanoma cells between proliferative and invasive states","volume":"68","author":"Hoek","year":"2008","journal-title":"Cancer Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"8755","DOI":"10.1038\/ncomms9755","article-title":"MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment","volume":"6","author":"Riesenberg","year":"2015","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ccell.2018.03.017","article-title":"Multi-stage differentiation defines melanoma subtypes with differential vulnerability to drug-induced iron-dependent oxidative stress","volume":"33","author":"Tsoi","year":"2018","journal-title":"Cancer Cell"},{"key":"B56","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1038\/ncomms7683","article-title":"Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state","volume":"6","author":"Verfaillie","year":"2015","journal-title":"Nat Commun"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nature11538","article-title":"Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation","volume":"490","author":"Landsberg","year":"2012","journal-title":"Nature"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0005","article-title":"Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2","volume":"3","author":"O\u2019Connell","year":"2013","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13046-024-02982-4","article-title":"Targeting HDAC6 improves anti-CD47 immunotherapy","volume":"43","author":"Gracia-Hernandez","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.873116","article-title":"Cancer cell phenotype plasticity as a driver of immune escape in melanoma","volume":"13","author":"Benboubker","year":"2022","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B62","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13046-025-03381-z","article-title":"Decitabine co-operates with the IL-33\/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma","volume":"44","author":"Noto","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"9529","DOI":"10.1200\/JCO.2017.35.15_suppl.9529","article-title":"ENCORE 601: A phase II study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with melanoma","volume":"35","author":"Johnson","year":"2017","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3305","article-title":"Entinostat plus pembrolizumab in patients with metastatic NSCLC previously treated with anti-PD-(L)1 therapy","volume":"27","author":"Hellmann","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.02.011","article-title":"BET-bromodomain inhibitors engage the host immune system and regulate expression of the immune checkpoint ligand PD-L1","volume":"18","author":"Hogg","year":"2017","journal-title":"Cell Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.024","article-title":"BET inhibition modifies melanoma infiltrating T cells and enhances response to PD-L1 blockade","volume":"139","author":"Nikbakht","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28607","article-title":"The advances in targeting CD47\/SIRP\u03b1 \u201cdo not eat me\u201d axis and their ongoing challenges as an anticancer therapy","volume":"15","author":"Gracia-Hernandez","year":"2024","journal-title":"Oncotarget"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-25-0531","article-title":"CD47\/SIRP\u03b1 immune checkpoint modulation: A synergistic strategy for next-generation CAR therapies","volume":"25","author":"Yousefi-Hashemabad","year":"2026","journal-title":"Mol Cancer Ther"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16020470","article-title":"Mechanisms of melanoma progression and treatment resistance: Role of cancer stem-like cells","volume":"16","author":"Al Hmada","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-CT072","article-title":"Abstract CT072: Efficacy and safety of entinostat (ENT) and pembrolizumab (PEMBRO) in patients with melanoma previously treated with anti-PD1 therapy","volume":"79","author":"Sullivan","year":"2019","journal-title":"Clin Trials"},{"key":"B71","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cell.2018.05.052","article-title":"LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade","volume":"174","author":"Sheng","year":"2018","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03250","article-title":"First-in-human phase I study of Iadademstat (ORY-1001): A first-in-class lysine-specific histone demethylase 1A inhibitor, in relapsed or refractory acute myeloid leukemia","volume":"38","author":"Salamero","year":"2020","journal-title":"J Clin Oncol"},{"key":"B73","unstructured":"An escalation\/expansion, open label, multicenter study of Iadademstat and Gilteritinib in patients with relapsed or refractory acute myeloid leukemia (R\/R AML) with FMS-like tyrosine kinase mutation (FLT3 Mut+): The FRIDA study\n          \n          \n          Clinicaltrials.Gov\n          \n          2024"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3\u2013related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.medj.2024.03.015","article-title":"Myeloid-T cell interplay and cell state transitions associated with checkpoint inhibitor response in melanoma","volume":"5","author":"Schlenker","year":"2024","journal-title":"Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1335","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma: The NIBIT-M4 clinical trial","volume":"25","author":"Di Giacomo","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1038\/s41467-023-40994-4","article-title":"Guadecitabine plus ipilimumab in unresectable melanoma: Five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial","volume":"14","author":"Noviello","year":"2023","journal-title":"Nat Commun"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114392","article-title":"Single-cell spatial multiomics reveals tumor microenvironment vulnerabilities in cancer resistance to immunotherapy","volume":"43","author":"Quek","year":"2024","journal-title":"Cell Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02053-5","article-title":"UK Biobank: A globally important resource for cancer research","volume":"128","author":"Conroy","year":"2023","journal-title":"Br J Cancer"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2026.106323","article-title":"A cancer biobank as a platform for basic and translational cancer research: Six years of experience","volume":"48","author":"de Andrade","year":"2026","journal-title":"Hematology Transfusion Cell Ther"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6074.IO2026-A036","article-title":"Abstract A036: Spatial multi-omics identifies a tumor microenvironment signature predictive of immunotherapy response in mucosal melanomas","volume":"14","author":"Ekmekcioglu","year":"2026","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:10:54Z","timestamp":1791285054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1932718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":83,"alternative-id":["10.3389\/fimmu.2026.1932718"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1932718","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1932718"}}